PPT-Understanding Aplastic Anemia

Anna Koget DO Aplastic Anemia An acquired stem cell disorder Idiopathic unknown etiology in 70 of the cases Diagnosis of exclusion Important to differentiate from other causes of Bone Marrow Failure . Mike Clark, M.D.. Anemia. is a decrease in the normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency.. Greg . Radin. 7/9/2013. Anemia. Definition:. Insufficient erythrocytes to carry O2 to peripheral tissues. Symptoms:. Tachycardia, DOE, decreased exercise . tol. , . pallor. . depend on severity and acuity.   . Seventh International Symposium in Continuing Nursing Education/March, 2014. 3/2014. Donald W. McLaren, MD. Objectives. To discuss how to evaluate and determine cause of anemia. To discuss Iron deficiency (ID) and Iron Deficiency Anemia (IDA) - causes, evaluation, signs, symptoms, treatment and prevention at different ages. Anthony Winchell. What is Fanconi Anemia?. http://www.sitemaker.umich.edu/nhowlett/files/fa-qr.gif. What is the Fanconi Anemia pathway?. http://www.hindawi.com/journals/anemia/2012/926787/. What is Fanconi Anemia Complementation Group L?. Laboratory Procedures. Anemia. Defined:. A condition of reduced oxygen carrying capacity of erythrocytes. Erythrocyte disorders. May be associated with. : . Decreased production of . RBC’s. Increased destruction of . Rafi Ahmed, MD. Hematology and Oncology Fellow. 4-10-14. Overview. Not a diagnosis, but a sign of disease. Warrants an investigation. Definition: Reduction in oxygen carrying capacity of blood due to decreased erythrocyte mass. Introduction. Epidemiology . Drug-induced Aplastic anemia. Drug-induced Hemolytic anemia. Drug-induced Neutropenia and Agranulocytosis. Drug-induced Thrombocytopenia. Drug-induced Megaloblastic anemia. CKD . Patients. 2012 KDIGO . Update. Dr. . Shahram. . Taheri. . CKD is a worldwide public health issue. . The incidence and prevalence of kidney failure are increasing, outcomes are poor, and the cost is high. . Agenda. 1.. 2.. 3.. 4.. Introduction. Introduction to Aplastic Anemia, its risk factors and epidemiolog. y . Mechanism . Look at the pathophysiology and the diagnosis of the disease . Next Steps. Take a closer look at research that is being done . Brooke . Bernhardt, . Pharm.D. ., . MS. , BCOP, BCPPS. Objectives. Recognize medications that may cause various blood count . abnormalities. Identify appropriate monitoring approaches for patients on medications that may cause . red blood cell mass . or . blood hemoglobin concentration. . In practice, anemia most commonly is defined by reductions in one or both of the following:. Hematocrit (HCT) – The HCT is the fractional volume of a whole blood sample occupied by RBCs, expressed as a percentage. As an example, the normal HCT in a child age 6 to 12 years is approximately 40 percent.. Allyson Pishko, MD MSCE. Assistant Professor. November 13, 2021. Disclosures. Research funding:. . Sanofi Genzyme. Outline. Paroxysmal Nocturnal . Hemoglobinura. (PNH). How? . Why. ?. Diagnosis. Signs/symptoms of PNH. Pancytopenia. Pancytopenia. . is a reduction in the blood count of all the major. cell lines – red cells, white cells and platelets. It has several causes. which . can be broadly divided into . decreased bone marrow . Dr. M. Sabloff. Director of the Leukemia Program at the Ottawa Hospital. October 13. th. 2018. Disclosures . Objectives. Aplastic anemia. Epidemiology. Treatment options. P. NH. Epidemiology. Treatment.